Sakar Healthcare Ltd

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 June 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.

At Rs 837.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sakar Healthcare Ltd locked at its upper circuit of 10% on 25 May 2026, with buyers queuing and no sellers willing to part with shares.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 15 May 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock’s current position as of 25 May 2026, providing investors with the latest insights into its performance and outlook.

A 143.23% stock return in one year. A 91.32% growth in net profit over the same period. The gap between those two numbers — roughly 52 percentage points — is driven by the market’s willingness to pay more for each rupee of Sakar Healthcare Ltd’s earnings. That willingness is the story behind this micro-cap’s multibagger status.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 14 May 2026. While the rating change occurred on this date, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s standing.

Sakar Healthcare Ltd., a Gujarat-based pharmaceutical company, delivered an exceptional fourth quarter for FY26, reporting net profit of ₹11.02 crores—a robust 91.32% surge year-on-year and a 7.51% sequential improvement from December quarter's ₹10.25 crores. The micro-cap pharma player, with a market capitalisation of ₹1,330.10 crores, demonstrated remarkable operational momentum as revenue climbed to ₹71.10 crores, marking a 41.52% year-on-year expansion and modest 1.08% quarter-on-quarter growth.

Sakar Healthcare Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This transition is supported by a confluence of technical indicators including MACD, moving averages, and Bollinger Bands, signalling renewed investor interest and potential upside in the Pharmaceuticals & Biotechnology sector.

At Rs 635.5, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Sakar Healthcare Ltd locked at its upper circuit of 20% on 12 May 2026, with buyers queuing and no sellers willing to part with shares.

Sakar Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 2.91%, the stock’s technical indicators present a nuanced picture, with some signals maintaining strength while others show caution. This article analyses the latest technical parameters, price momentum, and relative performance against the Sensex to provide a comprehensive view for investors.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 03 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 22 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 April 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

A 145.78% stock return in one year. A 69.3% growth in net profit over the same period. The gap between those two numbers — roughly 76 percentage points — is driven largely by the market's willingness to pay a significantly higher multiple for each rupee of Sakar Healthcare Ltd's earnings. That willingness is the story behind this micro-cap's multibagger status.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 31 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of its performance and prospects.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 09 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.